MedTrace Logo

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis

NCT04512833 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-06-27

No results posted yet for this study

Summary

The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.

Conditions

Interventions

RADIATION

Cyberknife stereotactic body radiation therapy

A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.

Sponsors & Collaborators

  • Beijing 302 Hospital

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2023-08-30
Completion
2026-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512833 on ClinicalTrials.gov